{"created":"2023-05-15T16:31:29.909986+00:00","id":2948,"links":{},"metadata":{"_buckets":{"deposit":"0eb01293-349e-4f14-ab4d-5cb414d750ab"},"_deposit":{"created_by":2,"id":"2948","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"2948"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00002948","sets":["29:30:1713167819629:214"]},"author_link":["13211","13219","13217","13214","13218","13212","13210","13215","13216","13213"],"item_3_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"157","bibliographicPageStart":"151","bibliographicVolumeNumber":"61","bibliographic_titles":[{"bibliographic_title":"Acta medica Nagasakiensia"}]}]},"item_3_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: Cases of schizophrenia are commonly complicated with obesity and diabetes mellitus partially caused by excessive eating associated with the use of second-generation antipsychotics (SGAs). We aimed to study the efficacy of glucagon-like peptide-1 in patients with schizophrenia under treatment with SGAs. Methods: Diabetic patients with schizophrenia were included if their HbA1c levels increased more than 1% and/or their weight increased more than 3 kg after treatment with SGAs. Patients who developed diabetes after treatment with SGAs were also included. The participants were treated with GLP-1 receptor agonists for one year, and their changes in weight and HbA1c and any adverse events were evaluated. Results: Seven patients were treated with GLP-1 receptor agonists; their mean age was 46.1 yrs old (range; 26 to 59), mean body weight was 85.3 kg (65.5 to 96.8), and mean BMI was 33.8 (27 to 38.7). Five of them showed improvement in their HbA1c levels of 1.2% (0.1 to 3.4, p=0.089) with a weight loss of 3.7 kg (-9.6 to +3.5, p=0.14) on average. The adverse effects observed were all gastrointestinal, but were not severe enough to cause termination of the GLP-1 receptor agonist treatment. The GLP-1 receptor agonist was not effective in one patient, and another patient terminated the treatment in a few months. Conclusions: Although the number of patients studied was small, GLP-1 receptor agonists seem to be effective for treating diabetes and bringing about weight loss in patients with schizophrenia under treatment with SGAs.","subitem_description_type":"Abstract"}]},"item_3_description_64":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Acta medica Nagasakiensia, 61(4), pp.151-157; 2018","subitem_description_type":"Other"}]},"item_3_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagasaki University School of Medicine"}]},"item_3_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00508430","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00016055","subitem_source_identifier_type":"ISSN"}]},"item_3_text_62":{"attribute_name":"sortkey","attribute_value_mlt":[{"subitem_text_value":"03"}]},"item_3_text_63":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"長崎大学医学部"}]},"item_3_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ando, Takao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hatada, Keiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sata, Misako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tachiki, Hitoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukazawa, Tetsuro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kusumoto, Shiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Horie, Ichiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Abiru, Norio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Matsumoto, Shunji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"ActMed61_151.pdf","filesize":[{"value":"528.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ActMed61_151.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/2948/files/ActMed61_151.pdf"},"version_id":"fe4c2178-222e-4f35-ac4a-b466ddb3d84e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"GLP-1 receptor agonist","subitem_subject_scheme":"Other"},{"subitem_subject":"schizophrenia","subitem_subject_scheme":"Other"},{"subitem_subject":"second-generation antipsychotics","subitem_subject_scheme":"Other"},{"subitem_subject":"weight gain","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics"}]},"item_type_id":"3","owner":"2","path":["214"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-05-10"},"publish_date":"2018-05-10","publish_status":"0","recid":"2948","relation_version_is_last":true,"title":["Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics"],"weko_creator_id":"2","weko_shared_id":2},"updated":"2024-04-16T05:25:49.145193+00:00"}